endoplasmic reticulum, which can actually be shown to hypertrophy after their use.2 This may explain why certain drugs, particularly barbiturates and meprobamate, become less effective and have a shorter duration of action with repeated use. Even patients with underlying liver disease are able to improve their hepatic metabolism to some extent by this method.3 This is probably the process by which the alcoholic becomes increasingly tolerant of alcohol. In the later stages, however, when liver damage has occurred, alcohol tolerance is diminished, probably owing to the reduction in the amounts of hepatic detoxicating enzymes, particularly alcohol dehydrogenase, in cirrhotic liver. Enzyme induction is nonspecific and is not confined to the enzymes actually concerned in the metabolism of the drug being administered. This principle of nonspecific enzyme induction has been applied therapeutically. A patient with deep, unconjugated hyperbilirubinaemia was given phenobarbitone in order to induce the enzymes which metabolize bilirubin and did indeed show a marked reduction in icterus.A
Drugs which Interfere with Bilirubin Metabolism
Drugs can interfere with the handling of bilirubin at all points in its passage from the reticulo-endothelial cell into the bile (see Fig.) . Drugs causing haemolysis increase the load of unconjugated bilirubin on the liver cell. Drugs such as sulphonamides or salicylates compete with serum albumin for binding with bilirubin. Flavaspidic acid, the active principle of male fern, interferes with the transport of bilirubin through the hepatic cell. Novobiocin inhibits the conjugation of the bilirubin as a glucuronide. All cholecystographic media compete with the conjugated bilirubin for excretion into the biliary canaliculus. Drugs which are C-17-substituted testosterone Conjugation I(Novblocin).. 
Nonspecific Changes in Liver Function due to Drugs
Transient changes in serum transaminase levels may be seen after many drugs. They follow the start of oral contraceptive therapy in a high proportion of patients. They may follow the administration of certain hypotensive and vasodilator drugs, some anti-inflammatory agents, and carbenoxolone sodium, and they may be found in workers exposed to hepatotoxic substances. If the drug is continued the biochemical changes usually revert to normal. Fluctuations in serum enzyme levels may be found in untreated, apparently normal persons, and it is exceedingly difficult to know the significance of these reactions in those taking various drugs. The serum enzymes concerned are virtually specific for liver injury, and elevation of the level presumably reflects a hepatic disturbance. The prognostic importance is uncertain. In doubtful cases the drug must be stopped and further investigations of liver function undertaken.
Conclusions Before a drug is given its possible hepatotoxic effects must be considered. Particular attention must be paid to the individual patient being treated, particularly to the age, underlying liver function, and the disease present. A drug should not be given if it carries even a small risk of causing a hepatic reaction and there is an equally effective therapeutic alternative.
A careful history of drug therapy, with identification of the drugs being given, is essential in any patient developing liver damage or jaundice.
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